StockDuty ← Dashboard Sep 09, 2026 08:05 AM ET
CatalystFDA/Bio

Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies

U.S. Department of War antibody program advancing to Phase 1 marks clinical milestone for Evotec Biologics.

What changed
U.S. Department of War antibody program advancing to Phase 1 marks clinical milestone for Evotec Biologics.
Why it matters
U.S. Department of War antibody program advancing to Phase 1 marks clinical milestone for Evotec Biologics. — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →